Concepts (174)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carotid Artery Diseases | 7 | 2020 | 101 | 1.780 |
Why?
|
| Dyslipidemias | 4 | 2017 | 114 | 1.520 |
Why?
|
| Hypolipidemic Agents | 6 | 2018 | 101 | 1.380 |
Why?
|
| Lipids | 4 | 2014 | 295 | 1.330 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2020 | 406 | 1.210 |
Why?
|
| Atherosclerosis | 5 | 2016 | 273 | 0.940 |
Why?
|
| Carotid Arteries | 4 | 2018 | 133 | 0.900 |
Why?
|
| Coronary Artery Disease | 4 | 2021 | 391 | 0.890 |
Why?
|
| Carotid Intima-Media Thickness | 3 | 2020 | 39 | 0.700 |
Why?
|
| Plaque, Atherosclerotic | 3 | 2018 | 61 | 0.600 |
Why?
|
| HIV Infections | 2 | 2020 | 1018 | 0.580 |
Why?
|
| Cause of Death | 1 | 2020 | 278 | 0.580 |
Why?
|
| Heart Sounds | 2 | 2025 | 2 | 0.580 |
Why?
|
| American Heart Association | 1 | 2017 | 118 | 0.490 |
Why?
|
| Primary Prevention | 1 | 2017 | 93 | 0.490 |
Why?
|
| Myocardial Contraction | 1 | 2017 | 193 | 0.480 |
Why?
|
| Cyclin D1 | 1 | 2016 | 86 | 0.470 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2016 | 156 | 0.450 |
Why?
|
| Pericardium | 1 | 2016 | 73 | 0.450 |
Why?
|
| Guideline Adherence | 1 | 2017 | 250 | 0.450 |
Why?
|
| Foramen Ovale, Patent | 1 | 2015 | 23 | 0.440 |
Why?
|
| Anticholesteremic Agents | 2 | 2016 | 164 | 0.430 |
Why?
|
| Carotid Stenosis | 2 | 2012 | 116 | 0.410 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 1397 | 0.400 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2012 | 3612 | 0.390 |
Why?
|
| Azetidines | 2 | 2016 | 38 | 0.390 |
Why?
|
| Adipose Tissue | 1 | 2016 | 280 | 0.390 |
Why?
|
| Thrombosis | 2 | 2015 | 318 | 0.380 |
Why?
|
| Cardiovascular Diseases | 3 | 2015 | 822 | 0.380 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2016 | 218 | 0.380 |
Why?
|
| Heart Diseases | 1 | 2015 | 269 | 0.370 |
Why?
|
| Heart Ventricles | 1 | 2017 | 664 | 0.370 |
Why?
|
| Coronary Stenosis | 1 | 2012 | 31 | 0.370 |
Why?
|
| Jejunum | 1 | 2012 | 78 | 0.360 |
Why?
|
| Intestinal Absorption | 1 | 2012 | 125 | 0.350 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 663 | 0.340 |
Why?
|
| Hypertension | 1 | 2017 | 788 | 0.330 |
Why?
|
| Cholesterol, HDL | 4 | 2017 | 173 | 0.330 |
Why?
|
| MicroRNAs | 1 | 2016 | 608 | 0.330 |
Why?
|
| Disease Progression | 4 | 2020 | 1615 | 0.320 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1116 | 0.310 |
Why?
|
| Cholesterol, LDL | 6 | 2018 | 250 | 0.280 |
Why?
|
| Blood Glucose | 1 | 2012 | 914 | 0.270 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2006 | 4 | 0.250 |
Why?
|
| Trypanosoma cruzi | 1 | 2006 | 8 | 0.250 |
Why?
|
| Middle Aged | 14 | 2020 | 29532 | 0.250 |
Why?
|
| Lipoproteins, HDL | 1 | 2006 | 92 | 0.240 |
Why?
|
| Humans | 25 | 2025 | 98362 | 0.240 |
Why?
|
| Heart Auscultation | 1 | 2025 | 3 | 0.220 |
Why?
|
| Male | 16 | 2025 | 47257 | 0.210 |
Why?
|
| Niacin | 4 | 2016 | 37 | 0.200 |
Why?
|
| Cardiology | 1 | 2025 | 125 | 0.200 |
Why?
|
| Risk Factors | 4 | 2020 | 6271 | 0.190 |
Why?
|
| Treatment Outcome | 6 | 2018 | 9770 | 0.180 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2018 | 283 | 0.180 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 360 | 0.180 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 4044 | 0.170 |
Why?
|
| Biomarkers | 4 | 2018 | 2021 | 0.170 |
Why?
|
| Incidence | 3 | 2015 | 1787 | 0.160 |
Why?
|
| Cell Proliferation | 2 | 2016 | 1791 | 0.150 |
Why?
|
| Heart Transplantation | 1 | 2006 | 874 | 0.150 |
Why?
|
| Time Factors | 4 | 2018 | 5576 | 0.150 |
Why?
|
| Students, Medical | 1 | 2025 | 449 | 0.150 |
Why?
|
| Clinical Competence | 1 | 2025 | 867 | 0.140 |
Why?
|
| Female | 12 | 2025 | 51756 | 0.140 |
Why?
|
| Coronary Angiography | 2 | 2012 | 238 | 0.140 |
Why?
|
| Lipoprotein(a) | 1 | 2018 | 33 | 0.130 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 923 | 0.130 |
Why?
|
| Compliance | 1 | 2017 | 16 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 889 | 0.130 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 48 | 0.130 |
Why?
|
| Chest Pain | 1 | 2017 | 44 | 0.130 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2016 | 14 | 0.120 |
Why?
|
| Antigens, Nuclear | 1 | 2016 | 29 | 0.120 |
Why?
|
| Linear Models | 1 | 2017 | 426 | 0.120 |
Why?
|
| Melanocytes | 1 | 2016 | 62 | 0.120 |
Why?
|
| 3' Untranslated Regions | 1 | 2016 | 102 | 0.120 |
Why?
|
| Proprotein Convertases | 1 | 2015 | 27 | 0.120 |
Why?
|
| Immunoblotting | 1 | 2016 | 273 | 0.110 |
Why?
|
| Heart Failure | 1 | 2006 | 1502 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2025 | 1126 | 0.110 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2015 | 17 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1009 | 0.110 |
Why?
|
| Adult | 8 | 2018 | 29587 | 0.110 |
Why?
|
| Clinical Trials as Topic | 3 | 2016 | 1126 | 0.110 |
Why?
|
| Cell Cycle | 1 | 2016 | 519 | 0.100 |
Why?
|
| Cisplatin | 1 | 2016 | 578 | 0.100 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2015 | 91 | 0.100 |
Why?
|
| Heptanoic Acids | 2 | 2011 | 73 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 526 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1296 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 325 | 0.100 |
Why?
|
| Pyrroles | 2 | 2011 | 166 | 0.100 |
Why?
|
| Apoptosis | 2 | 2016 | 1752 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2020 | 3227 | 0.090 |
Why?
|
| Ezetimibe | 1 | 2012 | 37 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 765 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2020 | 2599 | 0.090 |
Why?
|
| Simvastatin | 2 | 2016 | 106 | 0.090 |
Why?
|
| Cell Line | 1 | 2016 | 2483 | 0.090 |
Why?
|
| Melanoma | 1 | 2016 | 524 | 0.090 |
Why?
|
| Smoking | 1 | 2015 | 676 | 0.080 |
Why?
|
| Global Health | 1 | 2013 | 215 | 0.080 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 2896 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2014 | 2009 | 0.080 |
Why?
|
| Age Factors | 1 | 2014 | 1974 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2016 | 1721 | 0.070 |
Why?
|
| Carotid Artery, Common | 1 | 2006 | 28 | 0.060 |
Why?
|
| Carotid Artery, Internal | 1 | 2006 | 74 | 0.060 |
Why?
|
| Gadolinium DTPA | 1 | 2006 | 239 | 0.050 |
Why?
|
| Aged | 3 | 2018 | 21844 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2381 | 0.050 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2006 | 152 | 0.050 |
Why?
|
| Double-Blind Method | 3 | 2018 | 1790 | 0.050 |
Why?
|
| United States | 1 | 2017 | 8258 | 0.050 |
Why?
|
| Educational Measurement | 1 | 2025 | 242 | 0.050 |
Why?
|
| Animals | 3 | 2015 | 28981 | 0.050 |
Why?
|
| Contrast Media | 1 | 2006 | 1013 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1785 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 2056 | 0.040 |
Why?
|
| Lipid Metabolism | 2 | 2011 | 221 | 0.030 |
Why?
|
| Colestipol | 1 | 2016 | 3 | 0.030 |
Why?
|
| Lovastatin | 1 | 2016 | 28 | 0.030 |
Why?
|
| Luciferases | 1 | 2016 | 128 | 0.030 |
Why?
|
| Hyperlipoproteinemias | 1 | 2015 | 7 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 139 | 0.030 |
Why?
|
| Triglycerides | 1 | 2016 | 234 | 0.030 |
Why?
|
| Proprotein Convertase 9 | 1 | 2015 | 37 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 310 | 0.030 |
Why?
|
| Receptors, LDL | 1 | 2015 | 54 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2015 | 69 | 0.030 |
Why?
|
| Streptokinase | 1 | 1995 | 10 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 301 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2016 | 293 | 0.030 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 1995 | 13 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 154 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 427 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 779 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 388 | 0.030 |
Why?
|
| Heart Valve Prosthesis | 1 | 1995 | 97 | 0.030 |
Why?
|
| Adipocytes | 1 | 2015 | 180 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 907 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 733 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 565 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2015 | 480 | 0.020 |
Why?
|
| Binding Sites | 1 | 2016 | 1160 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 980 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 1995 | 261 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2015 | 310 | 0.020 |
Why?
|
| Idaho | 1 | 2011 | 9 | 0.020 |
Why?
|
| Apolipoproteins B | 1 | 2011 | 38 | 0.020 |
Why?
|
| Washington | 1 | 2011 | 53 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 2858 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 219 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 589 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 1230 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 845 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2011 | 4817 | 0.020 |
Why?
|
| Fibrosis | 1 | 2011 | 234 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2016 | 2070 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 1419 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 1102 | 0.020 |
Why?
|
| Colesevelam Hydrochloride | 1 | 2007 | 11 | 0.020 |
Why?
|
| Allylamine | 1 | 2007 | 14 | 0.020 |
Why?
|
| Calcium | 1 | 2011 | 1203 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 7418 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 2579 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2016 | 3633 | 0.010 |
Why?
|
| Brain | 1 | 2015 | 2439 | 0.010 |
Why?
|
| Mutation | 1 | 2015 | 4428 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1995 | 2687 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 12735 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2792 | 0.010 |
Why?
|
| Prosthesis Design | 1 | 1995 | 309 | 0.010 |
Why?
|